Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

gentry pharmaceuticals ltd. - butaphosphan + cyanocobalamin - injection - 10 gm + 5 mg/100 ml

Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

gentry pharmaceuticals ltd. - dexamethasone sodium phosphate - injection - 2 mg/ml

Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

gentry pharmaceuticals ltd. - ivermectin - injection - 10 mg/ml

Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

gentry pharmaceuticals ltd. - marbofloxacin - injection - 100 mg/ml

Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

gentry pharmaceuticals ltd. - tolfenamic acid - injection - 4 gm/100 ml

Kanada - englanti - Health Canada

mint pharmaceuticals inc - levofloxacin (levofloxacin hemihydrate) - tablet - 250mg - levofloxacin (levofloxacin hemihydrate) 250mg - quinolones

Kanada - englanti - Health Canada

mint pharmaceuticals inc - levofloxacin (levofloxacin hemihydrate) - tablet - 750mg - levofloxacin (levofloxacin hemihydrate) 750mg - quinolones

Kanada - englanti - Health Canada

mint pharmaceuticals inc - levofloxacin (levofloxacin hemihydrate) - tablet - 500mg - levofloxacin (levofloxacin hemihydrate) 500mg - quinolones

Yhdysvallat - englanti - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - ethinyl estradiol 0.02 mg - blisovi fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. adapted from ra hatcher et al, reference 7. oral contraceptives are contraindicated in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - current diagnosis of, or history of, breast cancer, which may be hormone sensitive - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy or jaundice with prior pill use - hepatic adenomas or carcinomas - are receiving hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations (see warnings, risk of liver enzyme elevations with concomitant hepatitis c treatment ).

Yhdysvallat - englanti - NLM (National Library of Medicine)

qualitest pharmaceuticals - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 1.5 mg